Who makes PF-06821497 Treatment E?

PF-06821497 Treatment E is developed by Pfizer Inc..

What development phase is PF-06821497 Treatment E in?

PF-06821497 Treatment E is in Phase 1.

What are the side effects of PF-06821497 Treatment E?

Common side effects include Headache, Vessel puncture site bruise, Nail avulsion, Neck pain, Disturbance in attention, Eyelid pain.

What is the generic name of PF-06821497 Treatment E?

pf-06821497-treatment-e is the generic (nonproprietary) name of PF-06821497 Treatment E.

Last reviewed 2026-04-20 · How we verify

PF-06821497 Treatment E (pf-06821497-treatment-e)

Pfizer Inc. · Phase 1 active Quality 5/100

At a glance

Generic name	pf-06821497-treatment-e
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Headache
Vessel puncture site bruise
Nail avulsion
Neck pain
Disturbance in attention
Eyelid pain
abdominal discomfort
Abdominal pain
Constipation
Nausea
Vessel puncture site pain
Fall

Key clinical trials

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-06821497 Treatment E CI brief — competitive landscape report
PF-06821497 Treatment E updates RSS · CI watch RSS
Pfizer Inc. portfolio CI